CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with moderately-to-severely active rheumatoid arthritis who had received limited or no treatment with DMARDs: efficacy and safety results from the 52-week phase 3 RA-BEGIN study
Authors
S Arthanari
I de la Torre
+19 more
P Durez
P Geusens
I Gjertsson
T Holzkämper
J Kekow
E Larsson
S Liu-Leage
S Otawa
G Pum
P Puttini
D Roccatello
V Rogai
S Shaikh
I Stoykov
S Süß
H Tahir
F van den Bosch
D Walker
O Zamani
Publication date
4 September 2017
Publisher
German Medical Science GMS Publishing House; Düsseldorf
Doi
Cite
Abstract
Abstract is not available.
Similar works
Full text
Available Versions
German Medical Science
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:oai-gms.dimdi.de:GM17dgrh1...
Last time updated on 09/07/2019